Mounjaro on the NHS: England’s 2026 access rules

NHS England’s phased plan prioritises people by BMI and specified conditions. Its table lists BMI 40 or above plus at least four qualifying conditions for cohort I; cohort II in 2026/27 covers BMI 35–39.9 plus at least four. The five conditions are hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease and type 2 diabetes. BMI thresholds are usually reduced by 2.5 for the ethnic backgrounds specified in the guidance. Later cohorts should not be treated as already open.

Your local ICB and prescribing service confirm how this is being delivered. Lancashire and South Cumbria, for example, published a reduction in its threshold from 23 June 2026. That is a useful local implementation example, not proof that every practice uses the same referral process.

NICE’s broader recommended group is adults with BMI at least 35 and at least one weight-related comorbidity, with appropriate lower thresholds for specified ethnic groups. England’s funding variation permits staged implementation. Being in that broader group does not automatically place someone in the current primary-care priority cohort.

The practical question is therefore more specific than “Do I qualify for Mounjaro?” Ask which pathway the clinician is considering, whether the service is accepting referrals and what the next assessment would involve. An internet checklist cannot make that decision.

Ask whether a specialist weight-management referral is clinically appropriate. This is an assessment of your needs, treatment history and available service, not a guaranteed route to a chosen medicine. Specialist-service implementation and primary-care prioritisation should not be collapsed into one rule.

Our provider guide explains where Oviva and regional examples fit. The provider’s NHS service may have different entry criteria and contact arrangements from any private offer shown on the same website.

NHS England’s primary-care tirzepatide pathway includes structured dietary, activity and behavioural support alongside monitoring. Before a programme starts, establish who delivers that support, how reviews are arranged and which team answers questions.

• Which service owns the referral and prescription?
• What information is needed before an assessment?
• How will appointments work around your access needs?
• Who should you contact if your health or circumstances change?
• What support can you use while waiting?

Keep a record of the medicine, prescribed dose, previous assessments and monitoring. A private prescription does not itself establish NHS funding entitlement. Discuss any proposed handover before stopping, switching or relying on a new supply route.

If private cost is part of that conversation, Monj is Med Easy’s reference for Mounjaro price comparisons. Compare the prescribed product and repeat terms; a first-order saving is not a reason to change a clinical plan.